MS and Demyelinating Disorders

The associate professor of neurology at Mayo Clinic Rochester, commented on biomarkers for identifying MS in patients, as well as the significance of new MS consensus guidelines.

Data suggest a link between different disease-modifying strategies and the occurrence of depression when treating patients with MS.

The neurologist from Banner Health and chief medical officer of the MS Association of America discussed the ongoing debate of when to administer high efficacy treatments throughout the MS disease progression.

The development of agents for MS to address the treatment needs of patients with progressive and relapsing disease has been an ongoing effort that has brought forth a few new potential disease-modifying therapies.

The associate professor of neurology at Mayo Clinic Rochester discusses the importance of alternative diagnoses and rarer presentations of MS, in order to avoid misdiagnoses and inappropriate treatment for patients.

Instead of a smooth-contoured, thin, and regular ring or arc typically seen, pattern 3 patients had atypical rings such as irregularly thick rings and arcs.

Here's what is coming soon to NeurologyLive.

Following the development and publication of consensus guidelines for the use of MRI in MS, Scott D. Newsome, DO, discusses next steps in adopting and implementing protocols to improve patient care.

Expert neurologists discuss the role of sphingosine-1-phosphate (S1P) receptor modulators in relapsing multiple sclerosis including vaccine considerations and pediatric use.

Key opinion leaders provide insight into the use cladribine for relapsing multiple sclerosis including durability and safety profile.

Orelabrutinib has the potential to inhibit B cell and myeloid cell effector functions in the central nervous system and may provide a clinically meaningful benefit on progression in all forms of MS.

Neurology News Network for the week ending July 17, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 15, 2021.

In discussion regarding the new MRI consensus guidelines for patients with MS, Scott D. Newsome, DO, and David Li, MD, FRCPC, discuss key points for their peers and colleagues.

These study results highlight the interest in immunosuppressive therapy taken before or during pregnancy and to reduce the risk of relapse during pregnancy and 1 year postpartum.

Chaired by Brian G. Weinshenker, MD, the presentations also feature Mayo Clinic experts W. Oliver Tobin, MBBCh, BAO, PhD; Jessica Stulc, MD, MPH; and Orhun H. Kantarci, MD. [WATCH TIME: 1 hour, 30 minutes]

Implementing new recommendations for the use of MRI in patients with MS will be a challenge in terms of education and adherence; Scott D. Newsome, DO, and David Li, MD, FRCPC, discuss the next steps to increase awareness for both patients and providers.

Scott D. Newsome, DO, and David Li, MD, FRCPC, discuss the impact of new MRI consensus guidelines for patients with multiple sclerosis.

Invalid and valid performers did not differ regarding demographic, patient-reported, and disease-related outcomes.

The data suggest that women considered at high relapse risk or with poor prognostic factors benefit peripregnancy from high-efficacy therapy continuation.

Serum GFAP levels showed consistent correlations with disease activity and the largest area under the ROC curve to differentiate attacks from remissions in individuals with NMOSD.

Here's what is coming soon to NeurologyLive.

Gavin Giovannoni, MD provides an overview of the development and pharmacodynamics of cladribine in multiple sclerosis.

Fred D. Lublin, MD, Ravi Dukkipati, MD, and Lauren Gluck, MD, discuss interferons and glatiramer as platform therapies in multiple sclerosis.

Total lesion volume and index lesion-related severity correlated with EDSS scores and cognitive performance, while volumetric cortical and subcortical gray matter correlated less strongly.